OBJECTIVE: Angiogenesis is regulated by the balance between pro- and antiangiogenic factors and by extracellular matrix protein interactions. Fibroblast growth factor 2 (FGF2) is a major proangiogenic inducer inhibited by the interaction with the soluble pattern recognition receptor long pentraxin 3 (PTX3). PTX3 is locally coexpressed with its ligand tumor necrosis factor-stimulated gene-6 (TSG-6), a secreted glycoprotein that cooperates with PTX3 in extracellular matrix assembly. Here, we characterized the effect of TSG-6 on PTX3/FGF2 interaction and FGF2-mediated angiogenesis. METHODS AND RESULTS: Solid phase binding and surface plasmon resonance assays show that TSG-6 and FGF2 bind the PTX3 N-terminal domain with similar affinity. Accordingly, TSG-6 prevents FGF2/PTX3 interaction and suppresses the inhibition exerted by PTX3 on heparan sulfate proteoglycan/FGF2/FGF receptor complex formation and on FGF2-dependent angiogenesis in vitro and in vivo. Also, endogenous PTX3 exerts an inhibitory effect on vascularization induced by FGF2 in a murine subcutaneous Matrigel plug assay, the inhibition being abolished in Ptx3-null mice or by TSG-6 treatment in wild-type animals. CONCLUSION: TSG-6 reverts the inhibitory effects exerted by PTX3 on FGF2-mediated angiogenesis through competition of FGF2/PTX3 interaction. This may provide a novel mechanism to control angiogenesis in those pathological settings characterized by the coexpression of TSG-6 and PTX3, in which the relative levels of these proteins may fine-tune the angiogenic activity of FGF2.
OBJECTIVE: Angiogenesis is regulated by the balance between pro- and antiangiogenic factors and by extracellular matrix protein interactions. Fibroblast growth factor 2 (FGF2) is a major proangiogenic inducer inhibited by the interaction with the soluble pattern recognition receptor long pentraxin 3 (PTX3). PTX3 is locally coexpressed with its ligand tumor necrosis factor-stimulated gene-6 (TSG-6), a secreted glycoprotein that cooperates with PTX3 in extracellular matrix assembly. Here, we characterized the effect of TSG-6 on PTX3/FGF2 interaction and FGF2-mediated angiogenesis. METHODS AND RESULTS: Solid phase binding and surface plasmon resonance assays show that TSG-6 and FGF2 bind the PTX3 N-terminal domain with similar affinity. Accordingly, TSG-6 prevents FGF2/PTX3 interaction and suppresses the inhibition exerted by PTX3 on heparan sulfate proteoglycan/FGF2/FGF receptor complex formation and on FGF2-dependent angiogenesis in vitro and in vivo. Also, endogenous PTX3 exerts an inhibitory effect on vascularization induced by FGF2 in a murine subcutaneous Matrigel plug assay, the inhibition being abolished in Ptx3-null mice or by TSG-6 treatment in wild-type animals. CONCLUSION: TSG-6 reverts the inhibitory effects exerted by PTX3 on FGF2-mediated angiogenesis through competition of FGF2/PTX3 interaction. This may provide a novel mechanism to control angiogenesis in those pathological settings characterized by the coexpression of TSG-6 and PTX3, in which the relative levels of these proteins may fine-tune the angiogenic activity of FGF2.
Authors: D Leali; M Belleri; C Urbinati; D Coltrini; P Oreste; G Zoppetti; D Ribatti; M Rusnati; M Presta Journal: J Biol Chem Date: 2001-07-25 Impact factor: 5.157
Authors: D Ribatti; M Presta; A Vacca; R Ria; R Giuliani; P Dell'Era; B Nico; L Roncali; F Dammacco Journal: Blood Date: 1999-04-15 Impact factor: 22.113
Authors: Svetlana A Kuznetsova; David J Mahoney; Gema Martin-Manso; Tariq Ali; Hilke A Nentwich; John M Sipes; Bixi Zeng; Tikva Vogel; Anthony J Day; David D Roberts Journal: Matrix Biol Date: 2007-10-25 Impact factor: 11.583
Authors: Rodrigo G Barros; Paula F Lima; Ana Caroline S Soares; Lorena Sanches; Christopher A Price; José Buratini Journal: J Assist Reprod Genet Date: 2019-03-18 Impact factor: 3.412
Authors: Akihiro Shindo; Takakuni Maki; Emiri T Mandeville; Anna C Liang; Naohiro Egawa; Kanako Itoh; Naoki Itoh; Mia Borlongan; Julie C Holder; Tsu Tshen Chuang; John D McNeish; Hidekazu Tomimoto; Josephine Lok; Eng H Lo; Ken Arai Journal: Stroke Date: 2016-03-10 Impact factor: 7.914
Authors: L Wirestam; H Enocsson; T Skogh; M L Eloranta; L Rönnblom; C Sjöwall; J Wetterö Journal: Clin Exp Immunol Date: 2017-03-31 Impact factor: 4.330
Authors: Cecilia Garlanda; Barbara Bottazzi; Elena Magrini; Antonio Inforzato; Alberto Mantovani Journal: Physiol Rev Date: 2018-04-01 Impact factor: 37.312